EE200000319A - hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon - Google Patents

hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon

Info

Publication number
EE200000319A
EE200000319A EEP200000319A EEP200000319A EE200000319A EE 200000319 A EE200000319 A EE 200000319A EE P200000319 A EEP200000319 A EE P200000319A EE P200000319 A EEP200000319 A EE P200000319A EE 200000319 A EE200000319 A EE 200000319A
Authority
EE
Estonia
Prior art keywords
hgrf
peg conjugates
intermediates
site
preparation
Prior art date
Application number
EEP200000319A
Other languages
English (en)
Estonian (et)
Inventor
Maria Veronese Francesco
Caliceti Paolo
Schiavon Oddone
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000319A publication Critical patent/EE200000319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EEP200000319A 1997-12-03 1998-12-01 hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon EE200000319A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (en) 1997-12-03 1997-12-03 Solution-phase site-specific preparation of GRF-PEG conjugates
PCT/EP1998/007748 WO1999027897A1 (en) 1997-12-03 1998-12-01 Site-specific preparation of polyethylene glycol-grf conjugates

Publications (1)

Publication Number Publication Date
EE200000319A true EE200000319A (et) 2001-08-15

Family

ID=8227732

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000319A EE200000319A (et) 1997-12-03 1998-12-01 hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon

Country Status (29)

Country Link
US (3) US6528485B1 (pl)
EP (2) EP0922446A1 (pl)
JP (2) JP2001524505A (pl)
KR (1) KR100561768B1 (pl)
CN (1) CN1149967C (pl)
AR (1) AR017780A1 (pl)
AT (1) ATE236607T1 (pl)
AU (1) AU755285B2 (pl)
BG (1) BG64815B1 (pl)
BR (1) BR9815159A (pl)
CA (1) CA2312004C (pl)
DE (1) DE69813291T2 (pl)
DK (1) DK1037587T3 (pl)
EA (1) EA004269B1 (pl)
EE (1) EE200000319A (pl)
ES (1) ES2194376T3 (pl)
HU (1) HUP0100507A3 (pl)
IL (2) IL136551A0 (pl)
NO (1) NO327238B1 (pl)
NZ (1) NZ504570A (pl)
PL (1) PL192082B1 (pl)
PT (1) PT1037587E (pl)
SI (1) SI1037587T1 (pl)
SK (1) SK8242000A3 (pl)
TR (1) TR200001615T2 (pl)
TW (1) TWI254641B (pl)
UA (1) UA73716C2 (pl)
WO (1) WO1999027897A1 (pl)
ZA (1) ZA9811068B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
ES2291613T3 (es) 2002-01-16 2008-03-01 Biocompatibles Uk Limited Conjugados de polimeros.
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
EP1585758A4 (en) * 2003-01-18 2006-06-07 Pegsphere Co Ltd PEPTIDES WITH PROTECTED AMINES OF UNCENTRICATED PLACES, METHOD OF MANUFACTURING THEREOF AND OF SPECIFICALLY CONJUGATED PEG-PEPTIDES THEREWITH
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
JP2008500005A (ja) * 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
CA2548179A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
JP4833862B2 (ja) * 2004-01-28 2011-12-07 サイトイミューン サイエンシズ インコーポレイテッド 官能化コロイド金属組成物および方法
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
US7632921B2 (en) 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
US20070027301A1 (en) * 2005-07-26 2007-02-01 Gabriella Cristobal-Lumbroso Polymers with pendant poly(alkyleneoxy) substituent groups and their use in personal care applications
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US7632492B2 (en) 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
CA2659990C (en) * 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
RU2345608C2 (ru) * 2007-01-09 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Северо-Кавказский государственный технический университет" Вареная колбаса с использованием pse свинины и способ ее производства
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009039502A1 (en) * 2007-09-21 2009-03-26 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
WO2010053990A2 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
HRP20161055T1 (hr) * 2009-03-20 2016-11-04 Hanmi Science Co., Ltd. Postupak proizvodnje konjugata specifičnog za mjesto od fiziološki djelotvornog polipeptida
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
JP5906184B2 (ja) 2009-06-22 2016-04-20 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
JP6113144B2 (ja) 2011-04-21 2017-04-12 セラテクノロジーズ・インコーポレーテッド 成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
EP3303378B1 (en) 2015-05-28 2021-04-21 Institut National de la Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
JP7134093B2 (ja) * 2016-04-19 2022-09-09 グリフォン・ファーマシューティカルズ・アンテルナシオナル・エスアー ペグ化バイオアクティブペプチド及びその使用
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
JP7665215B2 (ja) 2019-12-19 2025-04-21 トランスフェルト・プラス・ソシエテ・アン・コマンディテ 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
CA3206260A1 (en) 2021-01-28 2022-08-04 Ilse Roodink Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
EP0544706A4 (en) * 1990-06-29 1993-10-13 Hoffmann-La Roche Inc. Histidine substituted growth hormone releasing factor analogs
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
WO1992018531A1 (en) * 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU7273196A (en) * 1995-11-03 1997-05-29 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
ZA9811068B (en) 1999-06-28
HK1034203A1 (en) 2001-10-19
EP1037587B1 (en) 2003-04-09
NO20002664L (no) 2000-07-13
US7317002B2 (en) 2008-01-08
CA2312004C (en) 2009-05-19
UA73716C2 (en) 2005-09-15
HUP0100507A2 (hu) 2001-08-28
AU755285B2 (en) 2002-12-05
JP5431874B2 (ja) 2014-03-05
WO1999027897A1 (en) 1999-06-10
SI1037587T1 (en) 2003-08-31
EP1037587A1 (en) 2000-09-27
US6869932B2 (en) 2005-03-22
CA2312004A1 (en) 1999-06-10
US20040029794A1 (en) 2004-02-12
EP0922446A1 (en) 1999-06-16
CN1149967C (zh) 2004-05-19
EA004269B1 (ru) 2004-02-26
US6528485B1 (en) 2003-03-04
CN1280483A (zh) 2001-01-17
JP2001524505A (ja) 2001-12-04
BG64815B1 (bg) 2006-05-31
PL192082B1 (pl) 2006-08-31
TWI254641B (en) 2006-05-11
NO327238B1 (no) 2009-05-18
ES2194376T3 (es) 2003-11-16
AU1563399A (en) 1999-06-16
ATE236607T1 (de) 2003-04-15
NZ504570A (en) 2003-10-31
BR9815159A (pt) 2000-10-10
JP2010024245A (ja) 2010-02-04
DK1037587T3 (da) 2003-07-28
EA200000601A1 (ru) 2000-12-25
NO20002664D0 (no) 2000-05-24
PT1037587E (pt) 2003-08-29
PL341139A1 (en) 2001-03-26
KR20010032494A (ko) 2001-04-25
AR017780A1 (es) 2001-10-24
BG104484A (bg) 2000-12-29
IL136551A0 (en) 2001-06-14
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
SK8242000A3 (en) 2001-01-18
KR100561768B1 (ko) 2006-03-16
WO1999027897A9 (en) 1999-09-30
TR200001615T2 (tr) 2000-12-21
US20050159353A1 (en) 2005-07-21
DE69813291D1 (de) 2003-05-15
DE69813291T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
EE200000319A (et) hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE03263B1 (et) Erütromütsiini derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja vaheühendid
EE03680B1 (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
HUP0102307A3 (en) Bispidine derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
FI973733L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04812B1 (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
EE04398B1 (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
NZ291597A (en) Carboxycyclopropan-1-yl derivatives, preparation, pharmaceutical compositions and intermediates thereof
HUP0000203A3 (en) Naphthyl derivatives, pharmaceutical compositions containing them and intermediates
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner